Zhonghua Yi Xue Za Zhi. 2026 May 19;106(18):1762-1766. doi: 10.3760/cma.j.cn112137-20260210-00447.
ABSTRACT
Pulmonary hypertension associated with left heart disease (PH-LHD) represents the most prevalent form of pulmonary hypertension. The concomitant elevation in pulmonary arterial pressure significantly exacerbates disease morbidity and mortality, leading to unfavorable prognosis. Despite sharing similar pathophysiological characteristics with pulmonary arterial hypertension (PAH), current clinical guidelines do not recommend PAH-targeted therapies for PH-LHD, as clinical trials conducted to date have failed to demonstrate the efficacy and safety benefits of such agents in PH-LHD patients. Novel therapeutic agents with distinct mechanisms-such as activin signaling inhibitors and long-acting relaxin analogs-have shown potential benefits in preliminary studies. It is anticipated that ongoing clinical investigations may yield favorable outcomes, thereby paving new avenues for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction and improving clinical prognosis.
PMID:42135043 | DOI:10.3760/cma.j.cn112137-20260210-00447